English|中文
English|中文

TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010

Time：2018-10-15

10/15/2018. TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010 in treatment of schistosomiasis advanced to clinical Phase I trial.



Previous： TongliBio announces to present development of TL-010 as an orphan drug at World Orphan Drug Congress
Next： ​TongliBio announces TL-010 was granted with orphan drug designation by FDA
Follow us:

Email：tl.office@tonglibio.com
Telephone：86-0512-58113269
Company Address：Rm 401, Bldg D, No.1 North Guotai Rd, Zhangjiagang, Suzhou, Jiangsu Province, PRC
苏ICP备13010604号

Verification code *
Submit
COPYRIGHT (©)  Tongli Biomedical Co. (TLB) Reserved 
Technical support: Three to Five Interconnection
TOP